TABLE 1.

Characteristics of included studies

Study	Sample size	Design	Age (years)	Male (%)	Hemorrhoid grade	Sucralfate dose	Control group	Outcomes a
Ala et al 31	48	Double‐blind RCT	41.5 ± 12.1	50%	Grade III and IV	Sucralfate 10%	Placebo	1,2,3,4,5,6
Albatanony et al 32	90	Double‐blind RCT	37.2 ± 10.7	45.5%	Grade III: 80% Grade IV: 20%	Sucralfate 10%	Placebo	1,2,3,4,5,6,7
Al Khateeb et al 33	50	Prospective RCT	41.2 ± 10.8	46%	Grade III: 54% Grade IV: 46%	Sucralfate 8%	Placebo	1,2,3,7
Alkhateep et al 34	95	Double‐blind RCT	42.4 ± 7.7	50.5%	Grade III: 77.8% Grade IV: 22.2%	Sucralfate 10%	Placebo	1,2,3,7
Gupta et al 35	116	Double‐blind RCT	44.9 ± 11	52.5%	Grade III: 74.1% Grade IV: 25.9%	Sucralfate 7%	Placebo	2,3,7
Vejdan et al 36	40	Single‐blind RCT	N/A	N/A	Grade III and IV	Sucralfate 10%	Placebo	1

^a Outcomes: 1 = VAS at 24 hours post‐operative; 2 = VAS at 7 days post‐operative; 3 = VAS at 14 days post‐operative; 4 = Pethidine used (mg) within 24 hours post‐operative; 5 = diclofenac used (mg) at 7 days post‐operative; 6 = diclofenac used (mg) at 14 days post‐operative; 7 = wound healing rate at 28 days post‐operative.